Results from a new study indicate that hybrid laboratory antibodies derived from chimpanzees and humans may provide a potentially safe and effective way to treat the serious complications that can occur following smallpox vaccination--and possibly may even protect against the deadly disease itself. The study, led by researchers with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), appears online this week in the Proceedings of the National Academy of Sciences (PNAS).

A worldwide immunization program officially eradicated naturally occurring smallpox disease in 1980. However, concerns of a bioterror attack involving the highly contagious and fatal virus have prompted researchers to search for new smallpox vaccines and treatments.

The currently licensed smallpox vaccine consists of a live but weakened strain of vaccinia virus, a relative of the variola virus that causes smallpox. Vaccinia immunization has been proven effective in generating immunity against smallpox virus and other orthopoxviruses, including monkeypox and cowpox.

Although most reactions to the vaccinia virus are mild, the vaccine can cause serious and even life-threatening complications in individuals with weakened immune systems or skin conditions such as eczema, in infants younger than 12 months and in pregnant women. Health care providers currently treat smallpox vaccine complications with anti-vaccinia immune globulin (VIG)--pooled antibodies taken from the blood of individuals immunized with the smallpox vaccine. However, VIG is in short supply since the United States discontinued its public smallpox vaccination program in 1972.

NIAID-funded researchers have been working to develop alternatives to VIG based on antibodies they created in the laboratory. The study appearing online this week in PNAS details how senior authors Robert H. Purcell, M.D., co-chief of NIAID's Laboratory of Infectious Diseas
'"/>

Contact: Kathy Stover
kstover@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
23-Jan-2006

Page: 1 2 3
Related medicine news :

1. Lilly studies try to shed light on impact of race
2. International studies show high efficacy for HPV vaccine
3. Innovative device to treat brain cancer shows promise in early studies
4. Limiting eligibility for medical studies can omit women and African-Americans
5. Making science personal: Lilly Oncology to unveil 76 studies at ASCO 2007
6. Epidemiology of TB: Updates from CDC studies to be presented at ATS 2007
7. DOE commits $27.5M for uranium contaminant transport field studies
8. Clinical studies evaluate potential treatments for mouth ulcers
9. Call for greater use of comparative effectiveness studies to help advance disease management
10. Americans still not eating enough fruits and vegetables, according to 2 recent studies
11. Queens studies find new links between wine, fermented foods and cancer